| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bluejay Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.58 |
| 52 Week High | US$13.98 |
| 52 Week Low | US$0.39 |
| Beta | 0.98 |
| 1 Month Change | 5.45% |
| 3 Month Change | -26.68% |
| 1 Year Change | -89.44% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.45% |
Recent News & Updates
Shareholder Returns
| BJDX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 15.5% | 1.6% | 1.7% |
| 1Y | -89.4% | 1.8% | 26.3% |
Return vs Industry: BJDX underperformed the US Medical Equipment industry which returned 1.7% over the past year.
Return vs Market: BJDX underperformed the US Market which returned 26.3% over the past year.
Price Volatility
| BJDX volatility | |
|---|---|
| BJDX Average Weekly Movement | 12.0% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BJDX's share price has been volatile over the past 3 months.
Volatility Over Time: BJDX's weekly volatility has decreased from 22% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 10 | Neil Dey | bluejaydx.com |
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis.
Bluejay Diagnostics, Inc. Fundamentals Summary
| BJDX fundamental statistics | |
|---|---|
| Market cap | US$1.56m |
| Earnings (TTM) | -US$9.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs BJDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BJDX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$9.74m |
| Earnings | -US$9.74m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.62 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BJDX perform over the long term?
See historical performance and comparison